University of Michigan-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of Michigan - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013579
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of Michigan (UM) is an educational service provider that offers educational and research services. The university offers graduate, undergraduate and post-doctoral levels programs in various disciplines. It operates various graduate schools and colleges of graduate studies, architecture, urban planning, education, engineering, information, kinesiology, law, medicine, music, theatre, dance, natural resources, environment, nursing and pharmacy. The university offers undergraduate studies in the areas of literature, science, architecture, urban, planning, art, design, business, education nursing, pharmacy and public policy. UM is headquartered in Ann Arbor, Michigan, the US.

University of Michigan – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of Michigan, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University of Michigan, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University of Michigan, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University of Michigan, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
University of Michigan, Medical Devices Deals, 2011 to YTD 2017 11
University of Michigan, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
University of Michigan, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Akadeum Life Sciences Raises USD1.5 million in Venture Financing 15
ViewPoint Therapeutics Raises USD4 Million in Series A Financing 16
Confo Therapeutics Raises USD7.3 Million Financing 17
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 18
Akadeum Life Sciences Raises USD1 Million in Financing Round 20
Partnerships 21
AstraZeneca Enters into Agreement with University of Michigan 21
Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 22
Tempus Labs Enters into Agreement with University of Michigan 23
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 24
IFM Therapeutics to Enter into Research Agreement with University of Michigan 25
Ohio State University and University of Michigan Enter into Agreement with Venture Therapeutics 26
Cardiavent Enters into Research Agreement with University of Michigan 27
University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 28
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 29
Galectin Therapeutics Enters Into Research Agreement With University of Michigan 30
Licensing Agreements 31
Nynex Therapeutics Enters into Licensing Agreement with University of Michigan 31
Calporta Therapeutics Enters into Licenisng Agreement with University of Michigan 32
ViewPoint Therapeutics Receives Technology Rights from University of Michigan and Washington University 33
ONL Therapeutics Enters Into Licensing Agreement with University Of Michigan and Massachusetts Eye and Ear Infirmary 34
Diapin Therapeutics Enters into Licensing Agreement with University of Michigan for ClopNPT 35
Heat Biologics Amends License Agreement with University of Michigan 36
Kura Oncology Amends its Licensing Agreement with University of Michigan 37
Diapin Therapeutics Enters into Licensing Agreement with University of Michigan 38
Ascentage Pharma Amends Licensing Agreement with Regents of the University of Michigan 39
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 40
Omni Sciences Enters Into Licensing Agreement With University of Michigan 41
NanoBio Enters Into Licensing Agreement With University Of Michigan 42
Medgenics Enters Into Licensing Agreement With Regents Of The University Of Michigan 43
Asset Transactions 44
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 44
University of Michigan – Key Competitors 45
University of Michigan – Key Employees 46
University of Michigan – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Joint Venture 48
Recent Developments 49
Strategy And Business Planning 49
Mar 16, 2017: Nynex Therapeutics Launched to Target Oncogenic Proteins in the Treatment of Cancer 49
Government and Public Interest 50
Nov 16, 2017: Study shows codeine prescribed to children despite FDA warning against it 50
Nov 02, 2017: Researchers Find Protein that Could Help Fight Antibiotic Resistance 51
Oct 31, 2017: NIH establishes new research in social epigenomics to address health disparities 52
Oct 10, 2017: NYU Dentistry Receives $2.8 Million as Part of Multi-Center Study to Stop the Progression of Cavities in Children 55
Sep 13, 2017: Michigan Medicine researchers awarded nearly $3.5 million to fight fatigue in multiple sclerosis 56
Aug 17, 2017: University of Michigan: Brain Imaging Study Shows How Acupressure Fights Fatigue in Breast Cancer Survivors 57
Jun 09, 2017: A SMARTer Way to Discover New Stroke Treatments 59
Dec 13, 2016: Physical activity good for your health, but what’s happening below the surface 61
Oct 26, 2016: Study Questions Benefits of Long-Term Home Oxygen Therapy for COPD Patients with Moderately Low Blood Oxygen Levels 62
Oct 20, 2016: $10.75 million gift funds depression research at the University of Michigan 64
Oct 17, 2016: FDA awards 21 grants to stimulate product development for rare diseases 66
Oct 04, 2016: Revolutionary Clinical Trial Initiative Focuses on Precision Medicine, Collaboration and Data Sharing to Transform Outcomes for All Pancreatic Cancer Patients 68
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 70
Aug 30, 2016: U-M researchers receive $3.9 million grant to accelerate musculoskeletal research program 72
Mar 07, 2016: Protein-revved stem cell could transform Alzheimer’s treatment 73
Mar 01, 2016: Study Hints at Regeneration of Nerve Insulation to Treat CHARGE Birth Defects 74
Feb 16, 2016: New Anti-biofilm Compounds Show Promise Against Drug-Resistant bacteria linked to Hospital Infections 75
Product News 77
Nov 24, 2016: Researchers at Children’s Hospital Los Angeles Identify Biomarker to Aid in Prognosis of Pediatric Ependymomas 77
Jun 22, 2016: UNC a lead site in clinical trial of three hepatitis C medications 78
Jun 14, 2017: Newest Port Company Revolutionizing Antibody Discovery Platforms 79
May 06, 2016: Researchers Report Progress as They Develop New Approach to Treating Metastatic Melanoma 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List of Tables
University of Michigan, Pharmaceuticals & Healthcare, Key Facts 2
University of Michigan, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University of Michigan, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University of Michigan, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University of Michigan, Deals By Therapy Area, 2011 to YTD 2017 10
University of Michigan, Medical Devices Deals, 2011 to YTD 2017 11
University of Michigan, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Akadeum Life Sciences Raises USD1.5 million in Venture Financing 15
ViewPoint Therapeutics Raises USD4 Million in Series A Financing 16
Confo Therapeutics Raises USD7.3 Million Financing 17
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 18
Akadeum Life Sciences Raises USD1 Million in Financing Round 20
AstraZeneca Enters into Agreement with University of Michigan 21
Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 22
Tempus Labs Enters into Agreement with University of Michigan 23
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 24
IFM Therapeutics to Enter into Research Agreement with University of Michigan 25
Ohio State University and University of Michigan Enter into Agreement with Venture Therapeutics 26
Cardiavent Enters into Research Agreement with University of Michigan 27
University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 28
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 29
Galectin Therapeutics Enters Into Research Agreement With University of Michigan 30
Nynex Therapeutics Enters into Licensing Agreement with University of Michigan 31
Calporta Therapeutics Enters into Licenisng Agreement with University of Michigan 32
ViewPoint Therapeutics Receives Technology Rights from University of Michigan and Washington University 33
ONL Therapeutics Enters Into Licensing Agreement with University Of Michigan and Massachusetts Eye and Ear Infirmary 34
Diapin Therapeutics Enters into Licensing Agreement with University of Michigan for ClopNPT 35
Heat Biologics Amends License Agreement with University of Michigan 36
Kura Oncology Amends its Licensing Agreement with University of Michigan 37
Diapin Therapeutics Enters into Licensing Agreement with University of Michigan 38
Ascentage Pharma Amends Licensing Agreement with Regents of the University of Michigan 39
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 40
Omni Sciences Enters Into Licensing Agreement With University of Michigan 41
NanoBio Enters Into Licensing Agreement With University Of Michigan 42
Medgenics Enters Into Licensing Agreement With Regents Of The University Of Michigan 43
PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 44
University of Michigan, Key Competitors 45
University of Michigan, Key Employees 46
University of Michigan, Subsidiaries 47
University of Michigan, Joint Venture 48

★海外企業調査レポート[University of Michigan-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SSandC Technologies, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SSandC Technologies, Inc. Merge …
  • Avanquest Software S.A. (AVQ):企業概要、財務及び戦略的SWOT分析
    Summary Avanquest Software SA (Avanquest) is an information technology company. The company develops and publishes personal and professional software. Its products include PC security, multimedia, disk management, PDF, backup software, home office, small business, communication tools, design, print, …
  • RUAG Holding AG:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' RUAG Holding AG Mergers and Acq …
  • SeqWright, Inc.(製薬・医療分野):企業M&A動向
    Summary SeqWright, Inc. (SeqWright) is a contract research organization. The company provides genomic services, such as the full-service nucleic acid technology CRO, molecular biology, to microarray, and next generation genomics. Its clinical trial services include FDA standard next gen, DNA sequenc …
  • Infineon Technologies AG:企業の戦略・SWOT・財務分析
    SummaryInfineon Technologies AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Ke …
  • SECI Energia SpA:企業のM&A・提携動向(エネルギー分野)
    Summary SECI Energia SpA (SECI Energia) is an energy development service provider that specializes in the construction, installation and management of plants. It focuses producing alternative energy through renewable. The company operates in the areas of thermoelectric power, biomass, solar, biogas …
  • Neograft Technologies Inc:企業のM&A・提携動向(医療機器分野)
    Summary Neograft Technologies Inc (Neograft) is a medical device company that cardiac technologies for use in heart bypass procedures. The company offers solutions such as saphenous vein harvesting, and coronary artery bypass graft. It develops and offers angioshield, which is a transformative techn …
  • Acorn Energy, Inc. (ACFN):企業のM&A・提携動向(エネルギー分野)
    Summary Acorn Energy, Inc. (Acorn) is an energy technology holding company. It provides technology solutions. The company through its subsidiaries offers Energy & Security Sonar solutions, Smart Grid Distribution Automation, and Machine-to-Machine Critical Asset Monitoring & Control services. Acorn’ …
  • Digi International, Inc. (DGII):企業の財務・戦略的SWOT分析
    Digi International, Inc. (DGII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Duke University(製薬・医療分野):企業M&A動向
    Summary Duke University (Duke) is an educational service provider. The university is comprised of schools and institutes including Pratt School of Engineering, Fuqua School of Business, Sanford School of Public Policy, School of Law, School of Medicine, Duke Kunshan University, Kenan Institute of Et …
  • ONGC Videsh Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' ONGC Videsh Limited Mergers and …
  • PDC Energy, Inc. (PDCE):企業の財務及び戦略的SWOT分析
    Summary PDC Energy, Inc. (PDC Energy) is an oil and natural gas company that offers operations such as production, development, exploration and marketing of crude oil, natural gas and natural gas liquids. The company also offers horizontal drilling and low-risk organic development of oil and natural …
  • Oil-Dri Corporation of America (ODC):企業の財務・戦略的SWOT分析
    Summary Oil-Dri Corporation of America (Oil-Dri) is a manufacturer and supplier of sorbent products. The company offers granular clay absorbents, universal absorbent products, oil only absorbents, haz mat, socks and boom, spill kits, sweeping compounds, and secondary containment products. Its univer …
  • United States Steel Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' United States Steel Corporation …
  • SEC Carbon Limited (5304):企業概要、財務及び戦略的SWOT分析
    Summary SEC Carbon Limited (SEC CARBON) is an artificial graphite electrode producer. The company's products include electrodes for aluminum smelting such as SK-Block, graphite electrodes, fine powder, batteries, paint, and others. It offers artificial graphite powder, natural graphite powder, and c …
  • Hard to Treat Diseases, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Hard to Treat Diseases, Inc. Me …
  • Sezmi Corporation (formerly Building B, Inc.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sezmi Corporation (formerly Bui …
  • Rogers Media, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Rogers Media, Inc. Mergers and …
  • Chemetall GmbH:企業の戦略的SWOT分析
    Chemetall GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Polo Resources Limited (POL):企業の戦略的SWOT分析
    Summary Polo Resources Limited (Polo Resources) is a natural resource and mine development investment company that selects, acquires and manages substantial investments in companies and projects. The compoany also invest in exploration companies. It invests in the gold, oil and gas, phosphate, coal …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆